Loading...
Please wait, while we are loading the content...
Similar Documents
Medición del pro péptido natriurético cerebral (probnp) para detección de daño miocárdico subclínico en pacientes con enfermedad de chagas
| Content Provider | Semantic Scholar |
|---|---|
| Author | Buteler, José Mores, Marina Velázquez, D. Rivolta, Susana Elvira Presti, Lo Strauss, Mélanie Miler, Natalia Rivarola, Hw |
| Copyright Year | 2017 |
| Abstract | 505 MEASUREMENT OF PRO-BRAIN NATRIURETIC PEPTIDE (PROBNP) FOR THE DETECTION OF SUBCLINICAL MYOCARDIAL DAMAGE IN PATIENTS WITH CHAGAS DISEASE 1Buteler J, 1Mores M, 2Velazquez D, 3Rivolta S, 2Lo Presti MS, 2Strauss M, 2Miler N, 2Rivarola HW Persona que presenta: Buteler J, butelerjavier@yahoo.com.ar Abstract: Chagas disease (CHD) is divided into: ACUTE CHD: symptomatic or asymptomatic and CHRONIC CHD: with or without demonstrated pathology. About 30-40% of the infected individuals develop the chronic phase with demonstrated pathology. The heart disease is the most frequent and severe clinical manifestation. Efforts focusing on the chronic phase without demonstrated pathology are crucial to prevent the installation of heart alterations. This stage lasts from 10 to 20 years and is characterized by positive serology but normal chest x-ray and electrocardiography. Myocardial damage however cannot be verified by the usual methods of study at this stage. Pro-Brain Natriuretic Peptide (proBNP) is a potent neurohormonal regulator with natriuretic and vasodilator actions; it also inhibits the sympathetic nervous system and the renin-angiotensin axis, and is secreted by the cardiac muscle, in response to pressure and/or volume overload. Its early detection could serve as a marker of progression and adverse prognosis. The objective of the present work was to determine the levels of proBNP in T. cruzi infected patients, ongoing the chronic phase of the infection, with or without demonstrated pathology. Patients (n = 80) from the San Roque Hospital, after signing informed consent, were studied through ELISA, HAI, electrocardiograms (ECG), Thorax RX, Ergometry and Doppler echocardiogram; then they were divided into: Control: with negative serology for CHD (36.6 ± 4.2 years); and in three groups with positive serology, G1: no ECG or structural alterations (49.5 ± 1.5 years); G2: with ECG alterations (56.55 ± 2.1 years) and G3: cardiomegaly and/or other structural alterations (57.17 ± 3.9 years). Non-infected patients were also studied. Blood samples were obtained from patients from all groups to determine ProBNP levels. Statistical analysis: ANOVA and Fisher's test. The results were: Control: 5.25 ± 0.09 pg / ml; G1: 30.85 ± 5.54 pg / ml; G2: 78.44 ± 13.84 pg / ml; G3: 1474.75 ± 363.9 pg / ml. Pro BNP levels in patients in the chronic phase of CHD without demonstrated pathology were higher ??(P <0.05) than those found in uninfected patients with similar clinical characteristics. Therefore, these results suggest that proBNP dosage could be an alternative in the detection of subclinical myocardial damage in patients with chronic stage CHD without demonstrated pathology. |
| File Format | PDF HTM / HTML |
| DOI | 10.31053/1853.0605.v0.n0.18332 |
| Alternate Webpage(s) | https://revistas.unc.edu.ar/index.php/med/article/download/18332/18195 |
| Alternate Webpage(s) | https://doi.org/10.31053/1853.0605.v0.n0.18332 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
